In the same procedure for clopidogrel resistance testing, ADP and other agonists are used to evaluate the effectiveness of clopidogrel's blockade of the P2Y12 (ADP) receptor. Significant inhibition (>50%) of ADP-induced platelet aggregation, with normal platelet response to an alternative agonist, such as thrombin receptor activating peptide (TRAP), indicates successful clopidogrel-induced platelet inhibition. This assay may also be used for other P2Y12 inhibitors such as prasugrel and ticagrelor.
